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1. Introduction 
Organisms belonging to the species Acinetobacter baumannii are capsulated coccobacillary, 
gram-negative bacteria. They can be found in the environment, will colonize various body 
tissues and food products and can persist on inanimate objects for a prolonged time period. 
Among the genus Acinetobacter, A. baumannii is the best described and most often associated 
with human disease and casualties. It is regarded as an opportunistic pathogen (1) and 
mostly targets susceptible hosts where it causes pneumonia, urinary tract infections, wound 
infections and meningitis. Over the last decade, we have witnessed a significant rise in the 
number and severity of cases of A. baumannii infections from hospital outbreaks as well as 
sporadic community-associated and wound-associated cases (2).  
It is believed that the ability of A. baumannii to persist in the environment, notably by 
forming protective biofilms, as well as its remarkable spectrum of antibiotic resistance have 
allowed it to emerge as a particularly problematic human pathogen (3, 4). Although these 
attributes appear to explain the resilience of this microbe, one must remember that a large 
array of innocuous bacterial species, including non-pathogenic members of the Acinetobacter 
genus, can resist antibiotics and form biofilms. Hence, the question of why A. baumannii is 
such a successful and lethal pathogen becomes more pertinent. Does it display additional 
unique features in its interactions with the host that favour successful colonization or 
infection? This chapter will bring together recent research in an attempt to answer these 
questions. It will strive to be both informative and perhaps inspire new strategies to better 
control this pathogen.  
2. Clinical manifestations of A. baumannii pneumonia 
The major risk factor for infection with A. baumannii, also seen as the one that increases the 
overall susceptibility of the host, is the use of an invasive procedure such as mechanical 
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ventilation during intensive care (5). Patients first become infected following colonization 
from the environment. Sources of contamination include surgical equipment, endotracheal 
or nasogastric tubes, catheters and previously colonized health care staff. The length of stay 
at the ICU has repeatedly been associated with increased risk of colonization and infection 
(5-7). Colonization is usually asymptomatic but will increase the likelihood of subsequent 
infection, which may proceed when the host natural barriers are weakened by trauma, 
surgery or other invasive procedures.  
Respiratory tract infections constitute a major portal of entry leading to A. baumannii 
bacteremia and are almost always hospital-acquired (8). Positive blood cultures are not 
commonly recognized in patients with nosocomial pneumonia (8). However, pneumonia 
caused by this organism are significantly more frequently associated with bacteremia and 
result in higher mortality rates (up to 50% of cases) (8). The clinical manifestations of A. 
baumannii lung infection, both in patients and in animal models, match those of the typical 
bacterial pneumonia, with alveolar congestion, edema and leukocytic infiltrations. 
Extracellular bacteria can be readily identified and cultured from lung biopsies and post-
mortem samples (8). Hence, it is alleged that bacteremia and sepsis are in most cases the 
final causes of death, not asphyxia and hypoxemia caused by pneumonia per se, although co-
morbidity significantly contributes to mortality (9). 
3. Multidrug resistance and antibiotic treatment 
Acinetobacter baumannii has acquired resistance to many antibiotics over the last two decades 
(10) and the incidence of infections caused by multi-drug resistant strains of A. baumannii 
have significantly increased worldwide. This has coincided with the appearance of 
carbapenem-resistant A. baumannii strains in North America, Asia, South America, South 
Africa and Australia. The global dissemination of carbapenem-resistant strains of A. 
baumannii demonstrates the success of this pathogen to cause epidemic outbreaks (11). A. 
baumannii appears able to acquire antibiotic resistance through multiple mechanisms such as 
over-expression of bacterial efflux pumps, changes in cell wall channels (porins), acquisition 
of extended-spectrum -lactamases, gene mutations and expression of certain enzymes that 
modify the metabolism of the antibiotic (reviewed in (12-17)). In addition, it is reported that 
the A. baumannii genome contains a “resistance island” with 45 resistance genes (18). A. 
baumannii can also rapidly acquire genetic entities for resistance, including some genes 
derived from other bacterial species (19). To date, A. baumannii strains have demonstrated 
resistance not only to ┚-lactams, aminoglycosides, fluoroquinolones, chloramphenicol, 
tetracycline, and rifampicin, but also to some relatively new antibiotics such as tigecycline, a 
novel broad-spectrum glycylcycline (20).  
The emergence of multi- and pan-drug resistant A. baumannii strains clearly presents 
significant challenges to the clinical management of the infection. The antibiotic selection for 
those A. baumannii strains is very limited. Despite its potential toxicity, polymyxin B and E 
(colistin) are probably the most commonly used and effective antibiotics for the treatment of 
resistant strains of A. baumannii at present (12, 14-16, 21-23). Other antibiotic candidates are 
tigecycline and imipenem (14, 21-24) but, as discussed above, resistance to tigecycline has 
developed in some A. baumannii strains (20). To combat the multidrug resistance of A. 
baumannii, it is also a common clinical practice to prescribe several antibiotics as a 
combination therapy although such practice remains controversial among the medical 
www.intechopen.com
 
Recent Advances in the Immunopathogenesis of Acinetobacter baumannii Infection 
 
25 
profession (12, 24). Although antibiotic resistance and clinical treatment are the most 
important aspects of the management of A. baumannii infection, this topic is out of the main 
scope of this chapter. Readers are referred to some recent excellent review articles on the 
details of antibiotic resistance mechanisms and the advances and challenges in the 
development of new therapeutics for the treatment of A. baumannii infections (12-17, 21-23).  
4. Experimental models of A. baumannii pneumonia 
Many clinical cases of A. baumannii have been rigorously described and are very informative 
about the disease course, risk factors and the prevalence of antibiotic resistance and other 
genetic traits in the isolates. However, these studies are not experimental in nature and are 
based on retrospective analysis of hospital-based cases. Thus, they generally fail to establish 
a causal relationship between the attributes of a given isolate and disease transmissibility, 
severity and clinical course, which define virulence. Knowledge of virulence factors can help 
both identify potentially dangerous pathogens before they strike and help develop new 
methods of control or treatments. Unfortunately, to date, aside from antibiotic-resistance 
genes, few virulence factors have been identified in A. baumannii (Table 1), despite wide 
variation in the ability of different laboratory strains and clinical isolates to cause disease in 
experimental models (25, 26). In addition, although a number of host factors have been 
examined for their potential involvement in the control of A. baumannii, only a few have 
been shown to play a role in resistance to infection (Table 2).  
 
Contributing factors Model Route of infection Readout Reference 
LPS Serum sensitivity in vitro Resistance to normal 
human serum 
(38) 
LPS Rat soft tissue 
Human serum 
Subcutaneous  
in vitro 
Bacterial 
growth/survival 
(39) 
Many genes and loci 
including urease 
Caenorhabditis 
elegans 
Dictyostelium 
discoideum 
in vitro Killing, egg count 
Plaque assay 
(34) 
OmpA A549 epithelial cells in vitro Adherence, apoptosis (42) 
OmpA A549 epithelial cells
Mouse 
in vitro
Intratracheal 
Invasion 
Blood counts 
(43) 
PBP-7/8 Rat soft tissue 
Rat pneumonia 
Human serum 
Subcutaneous 
Intratracheal 
in vitro 
Bacterial 
growth/survival 
(46) 
Phospholipase D Human serum 
Epithelial cells 
Mouse 
in vitro
in vitro 
Intranasal 
Growth 
Invasion 
Blood counts 
(47) 
pmrB Mouse Intraperitoneal Survival, microbial 
growth in spleen 
(35) 
ptk, epsA, capsule Human ascites fluid 
Rat soft tissue 
in vitro
Subcutaneous 
Bacterial 
growth/survival 
(40) 
RecA Macrophages 
Mouse 
in vitro
Intraperitoneal 
Bacterial survival 
Mortality 
(50) 
Table 1. Identified virulence factors of A. baumannii 
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Resistance 
factors 
Model Route of 
infection 
Readout Noncontributing 
factors 
Reference 
Acute-phase 
response and 
serum amyloid 
A (negative 
effect) 
Mouse, 
turpentine 
acute phase 
model 
Intranasal Lung bacterial 
burdens 
TNF-┙ (69) 
CD14, TLR4 Mouse Intranasal Bacterial growth TLR2 (65) 
Complement Human 
serum 
in vitro Bacterial 
growth/survival 
N/A (29, 45) 
NADPH 
oxidase 
Mouse Intranasal Lung and spleen 
bacterial burdens 
NOS2 (71) 
Neutrophils Mouse, 
systemic 
Intraperitoneal Survival, bacterial 
burden in organs 
Sex, strain, IL-17A, 
KC 
(25) 
Neutrophils, 
MIP-2 
Mouse, two 
strains 
Intranasal Lung and spleen 
bacterial burdens 
N/A (28, 70) 
Table 2. Identified host factors that are important in resistance to A. baumannii infection 
The most widely used model for the study of A. baumannii virulence and host responses is 
based on the mouse (26-28). It has been exploited to study pneumonia as well as septicaemia 
caused by A. baumannii and was successful in identifying or validating both microbial 
virulence and host resistance factors. Overall, conventional mice (such as C57BL/6 and 
BALB/c) show relatively high resistance to respiratory infection with A. baumannii. Mice 
inoculated intranasally with up to 108 viable A. baumannii develop an acute, self-limiting 
bronchopneumonia and infected mice generally clear the infection by 96 hours after 
inoculation (28). Moreover, the infection is usually limited to the respiratory tract with 
minimal systemic dissemination. As expected, treatment of mice with immunosuppressive 
drugs (such as cyclophosphamide) greatly exacerbate the infection and can convert an 
otherwise self-limiting infection into a lethal one (27). In addition, a rat model has been 
established and used to study both pneumonia and soft tissue injury (29). Human studies 
are so far limited to bactericidal assays using serum or ascites fluid and the use of human 
peripheral blood mononuclear cells and various epithelial cell lines (29-33). More basic in 
vivo models involving inhibition of Caenorhabditis elegans and Dictyostelium discoideum were 
employed for screening the virulence of multiple A. baumannii transposon insertional 
mutants (34). In many studies, more than one aspect of virulence was explored to generate a 
more complete picture. 
5. Virulence factors of A. baumannii 
One of the defining attributes of A. baumannii, both biologically and clinically, is its ability to 
resist a number of antibiotic classes. It is often debated whether antibiotic resistance genes 
can be considered virulence factors. On the one hand, they do contribute to the capacity of 
the pathogen to cause disease by resisting treatment. On the other hand, they do not directly 
affect the natural course of the infection and only play a role when an exogenous 
chemotherapeutic compound is administered. However, this distinction is blurred when 
that resistance to antibiotics impacts on virulence in the absence of the antibiotic. For 
instance it was reported that colistin-resistant A. baumannii isolates show a general lower 
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fitness as assessed by animal mortality and bacterial burdens in organs (35). The mutation 
conferring antibiotic resistance was mapped to the pmrB gene. The pmrABC operon mediates 
resistance to colistin and other polymyxins through modification of the lipid A portion of 
LPS (36). Polymyxins bind to LPS; resistance can occur by the complete loss of lipid A 
through disruption of the biosynthetic genes, yielding LPS-deficient, Gram-negative bacteria 
(37). LPS was identified in at least two independent studies as contributing to bacterial 
virulence. It was first found to be important for serum resistance whereas capsular 
polysaccharide was dispensable (38). This was recently reproduced and further investigated 
in a wound infection model where LPS was found to be important for bacterial growth and 
survival (39). Hence, it is not surprising that downregulation of LPS as a means to resist 
polymyxins will significantly impact the virulence of the organism and might explain the 
low prevalence of colistin resistance in clinical isolates (21). 
While capsular polysaccharides may not be required for serum resistance, the capsule was 
shown to be a major contributor to virulence since the growth of capsule-deficient variants 
of A. baumannii was attenuated in human ascites fluid and in a wound infection model (40). 
Hence, it is evident that different virulence factors may be manifest at distinct stages and 
physiological locations of the infection. Another iteration of that concept is found with outer 
membrane protein A (AbOmpA), a porin-like protein of A. baumannii which appears to 
mediate multiple functions. This protein is homologous to OmpA proteins from 
Enterobacteria and outer membrane protein F (OprF) of Pseudomonas sp. (41). AbOmpA was 
reported to mediate cytotoxicity in human HEp-2 cells (32) and dendritic cells (33). It also 
mediates interaction and invasion of lung epithelial cells as wells as biofilm formation on 
abiotic surfaces (42, 43). Whether these in vitro events (attachment, invasion and apoptosis) 
are important for in vivo virulence is still uncertain. Moreover, AbOmpA was recently 
shown to play a role in iron metabolism, another feature that may impact virulence (44). In 
this regard, blood dissemination of OmpA-deficient bacteria was less pronounced in the 
mouse pneumonia model (43), suggesting that this protein influences virulence at one or 
many of the steps leading to bacteremia. One of these steps could be resistance to 
complement-mediated lysis (45). 
Random transposon mutagenesis has the potential to provide a large amount of unbiased 
information about microbial virulence. In the last few years, this approach has been adapted 
for the study of A. baumannii physiology and pathogenesis. The first study reported by 
Michael G. Smith and colleagues (2007) combined high-density pyrosequencing with 
transposon mutagenesis and identified a number of putative pathogenicity loci (34). Their 
screen was based on inhibition of Dictyostelium and Caenorhabditis elegans by A. baumannii 
mutants. They reported that a large proportion of the pathogen’s genome consisted of 
foreign DNA and found six islands associated with virulence. This underlined once more 
the ability of this pathogen to adapt and evolve by acquiring genetic material for antibiotic 
resistance and virulence. While informative, this screen was only a first step since the 
mutants were not complemented nor were they tested in a mammalian model. More 
recently, Russo et al. (2009) identified a putative low-molecular-mass penicillin-binding 
protein 7/8 (PBP-7/8) as a virulence gene based on serum sensitivity and validated it in the 
rat models of pneumonia and soft tissue infection (46). PBP-7/8 affects cell morphology and 
is suspected to play a role in peptidoglycan synthesis and cell wall structure. A similar 
mutagenesis study using serum sensitivity as the readout and pneumonia as the validation 
step identified phospholipase D (PLD) as a bona fide virulence factor (47). Interestingly, PLD 
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is also associated with virulence in Neisseria gonorrhoeae (48) and Corynebacterium 
pseudotuberculosis (49). Hence this enzyme could be used as a drug target for the design of 
novel antimicrobials. 
Another bacterial enzyme that was recently shown to play a role in virulence is recA (50). This 
protein was found not only to mediate DNA repair in A. baumannii but also played a role in 
desiccation resistance, prevented killing inside macrophages as well as contributed to mouse 
lethality. It may be argued that such a pleotropic protein may not qualify as an authentic 
virulence factor, for which the defining function is to ensure development inside a live host 
independently of in vitro or environmental fitness. Nevertheless, recA shows promise as a 
specific antimicrobial target and its implication in virulence underscores the importance of a 
microorganism’s DNA repair pathway in the battle between host and pathogen. 
6. Biofilm formation 
One of the hallmark features of the Acinetobacter genus is the ability to form biofilms on 
animate and inanimate surfaces. Biofilm formation is associated with bacterial persistence in 
chronic diseases and in the environment; however, it is not yet clear whether production of 
biofilms by A. baumannii is involved in virulence. A high level of heterogeneity has been 
observed between isolates with respect to biofilm formation, which could not be correlated 
with virulence or disease severity (51-53). Moreover, biofilm production and adherence to 
airway epithelial cells is also observed at similar frequencies in low virulence species of 
Acinetobacters (30). Nevertheless, biofilm formation may contribute to disease transmissibility 
by promoting survival of A. baumannii on surgical instruments, catheters and external body 
surfaces and enabling colonization. It is likely that a combination of features, including the 
various virulence factors, resistance to multiple antibiotics and general hospital infection 
management etc., make A. baumannii a successful clinical pathogen.  
7. Iron acquisition 
One last feature that is under scrutiny is the role of iron in A. baumannii pathogenesis. Iron is a 
redox metal essential to most life forms; it is a component of many enzymes and factors such 
as ribonucelotide reductase (54) and the cytochromes of the aerobic electron transport chain 
(55). Although abundant inside the body, iron is usually found in association with host 
macromolecules like heme and transferrin and, thus, is not readily available to bacteria. As a 
result, A. baumannii must develop strategies to capture and retain iron for its survival and 
growth. Using a proteomics-based approach, 58 proteins were found to be differentially 
expressed in A. baumannii in response to iron modulation, including AbOmpA (44). Although 
the importance of iron acquisition in pathogenesis has not been experimentally established, 
this suggests that A. baumannii has evolved sophisticated regulatory mechanisms to respond to 
iron deprivation which are meant to ensure survival in the host, where this metal is scarce.  
The production of siderophores is one strategy used by the pathogen to grow under iron-
limiting conditions (56, 57). Siderophores are small secreted molecules that bind iron with high 
affinity and can be taken up by bacteria as a way to scavenge trace iron from their 
surroundings. The siderophore produced by the A. baumannii type strain 19606 was termed 
“acinetobactin” (58). It is structurally related to the siderophore produced by Vibrio anguillarum 
and resembles catechol-type siderophores such as the enterobactins (59). Of note, A. baumannii 
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isolates often differ in the structure of the siderophores and other iron acquisition factors they 
express (60). Another way that A. baumannii can acquire iron in the circulation is by utilizing 
hemin, a salt of heme generated from the breakdown of hemoglobin (61). Conversely, A. 
baumannii cannot use hemoglobin itself (61) and does not bind the iron transporter transferrin 
(57), unlike other gram-negative bacteria such as Neisseria and Moraxella (62).  
The importance of iron metabolism was also supported by the discovery that a novel 
monobactam-class antibiotic, BAL30072, is particularly active against A. baumannii when 
tested against a panel of pathogenic gram-negative species (63, 64). BAL30072 is a catecholic 
┚-lactam that binds iron and acts as a siderophore (63). Under iron-restricted conditions 
such as those encountered in vivo, the molecule would be taken up efficiently by the 
bacteria’s siderophore capture machinery, acting as a Trojan horse to deliver the antibiotic 
inside the cell. Hence it is possible that a microorganism with a high avidity for iron and 
siderophores, such as A. baumannii, might be more easily targeted and killed by antibiotics 
of this class. As a bonus, resistance might appear by downregulating siderophore uptake 
but only at the expense of in vivo fitness. 
8. Host resistance factors 
Like A. baumannii virulence factors, host factors important for protection against A. 
baumannii infection are still largely unexplored. It is generally recognized that 
immunocompromised individuals are much more likely to become infected by A. baumannii, 
an opportunistic pathogen by most definitions (1). As such, the host innate immune system 
is generally successful in controlling the pathogen and that only when it fails does the 
infection progress, such as upon barrier disruption, severe stress or immunosuppressive 
drug treatment. Identification of host immune cells and molecules that are critical for 
resistance could help us better deal with these deadly infections by monitoring those factors 
and boosting or supplementing them as the need arises. 
Infections with A. baumannii are characterised by an acute, rapid progression. The host 
appears to either control the infection or becomes overwhelmed by it. This implies that 
innate immunity plays a major role in the control of this pathogen. Indeed, CD14 and TLR4, 
members of the innate immune system and the LPS sensing pathway, have been shown to 
be essential for resistance to A. baumannii infection in a knockout mouse model, while TLR2 
appeared to counteract the robustness of the induced innate immunity (65).  
The importance of LPS sensing would be consistent with a strong, protective pro-
inflammatory reaction against the pathogen. Paradoxically, trauma and postsurgical patients 
mounting a strong systemic acute-phase response are more susceptible to A. baumannii 
infections (66-68). Experimentally, an acute-phase response elicited in mice with turpentine or 
by direct injection of exogenous serum amyloid A protein reduced pulmonary inflammation 
and neutrophil migration during A. baumannii pneumonia (69). This treatment ultimately led 
to enhanced susceptibility in the mice. This phenomenon might explain part of the 
immunosuppression that permits the microbe to successfully infect hospital patients. Hence, 
control of A. baumannii probably requires a targeted and self-limiting inflammatory response. 
Major effectors of the innate inflammatory response, neutrophils play a critical role in the 
control of A. baumannii infection, as would be expected when dealing with extracellular 
bacteria. They are rapidly recruited to the lungs after infection and contribute to its 
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resolution. Early animal models of A. baumannii pneumonia used cyclophosphamide to 
render mice neutropenic (24, 27) which might have increased the magnitude of bacterial 
replication in vivo, although this was not addressed directly. The role of neutrophils was not 
formally investigated until much later when it was found that antibody-mediated depletion 
of neutrophils resulted in an acute lethal infection in mice that was associated with 
enhanced bacterial burdens in the lung and extrapulmonary dissemination to the spleen 
(28). Conversely, enhanced pulmonary recruitment of neutrophils by intranasal 
supplementation of the chemoattractant MIP-2 promoted clearance of the pathogen (28). 
The importance of neutrophils and of the regulation of their trafficking was reinforced when 
it was shown that A/J mice are more susceptible to A. baumannii compared to C57BL/6 mice 
due to a delayed and weaker neutrophil recruitment (70). Strain differences in host 
responses are common and may lead to genetic studies uncovering novel resistance factors. 
However, the choice of strains, route of infection and measurements might be of prime 
importance since another study did not report differences between their experimental 
mouse strains when doing Intraperitoneal injections (25) while a third found differences in 
mortality but not in lung bacteriology when comparing three murine strains (27). 
The role of neutrophils was further investigated at the molecular level to determine what 
effector functions were required for clearance of A. baumannii. It was found that NADPH 
phagocyte oxidase expressed in neutrophils played a major role in extrapulmonary 
dissemination of A. baumannii whereas the contribution of inducible nitric oxide synthase 
(NOS2) was minor (71). This is consistent with evidence that NOS2 may be predominantly 
restricted to the control of intracellular pathogens (72). Other factors suspected to play a role 
such as sex, IL-17A and the chemokine KC (CXCL1) were also ruled out (25). Still 
unresolved is the role of the lung macrophages and epithelial cells in the initial recognition 
of the pathogen and subsequent recruitment of neutrophils. Are these cell types and others 
involved in recruiting neutrophils to the site of infection? Is infection of epithelial cells 
essential for the translocation of the pathogen into the circulation? Many of the initial steps 
of A. baumannii infection remain unexplored. 
In the bloodstream, A. baumannii would encounter other hurdles to infection and 
dissemination. Blood contains a number of innate immune components that can restrict 
bacterial growth and even kill a large proportion of infecting microorganisms. Human 
serum is bactericidal or bacteriostatic to most strains of A. baumannii and this was shown to 
be mediated by complement (29, 45). The alternative complement pathway is responsible for 
killing the bacteria (45, 51). Interestingly, serum resistance in some strains was explained by 
the binding of Factor H, an inhibitor of this pathway, to A. baumannii outer membrane 
proteins, including AbOmpA (45). However, this is not a universal phenomenon since 
binding to Factor H was not observed in another set of serum-resistant isolates (51).  
There is clearly a substantial amount of variability in both the serum sensitivity of the 
pathogen and the bactericidal activity of sera from different individuals (38, 73). This could 
be due to past exposures and the presence of circulating antibodies. Lifelong exposure to 
Acinetobacter species from the environment might confer some low level of immunity to the 
pathogen. Indeed, both active and passive immunization using an inactivated whole cell 
vaccine are very effective at preventing A. baumannii infection in mice (74). This could 
explain why blood from naïve mice does not show any inhibitory activity towards A. 
baumannii (unpublished observations) and would suggest that blood does not contain 
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significant natural defences against the pathogen, a state that could prove detrimental to the 
susceptible, naïve host. 
9. Conclusion 
Acinetobacter baumannii presents an array of features that make it a particularly troublesome 
pathogen. Similar to other emerging gram-negative bacilli like Pseudomonas aeruginosa and 
Klebsiella pneumonia, its quick rise in the past decades is probably the result of an ability to 
rapidly evolve and acquire new genetic material for virulence and antibiotic resistance. The 
multidrug resistance of several isolates of A. baumannii can be traced back to multiple events 
including downregulation of porins, expression of drug-inactivating enzymes and target 
alterations (75). Furthermore, the ability of A. baumannii to form biofilms allows it to persist 
on abiotic surfaces, a first step in disease transmission. When it finds an appropriate niche, 
such as the lung, it rapidly multiplies and creates a localized infection or colonization. If this 
infection is not contained effectively because of treatment failure or ineffective host defense 
mechanism, bacteremia will rapidly progress which may prove fatal. 
Fast-growing in nature and able to overwhelm host defences, A. baumannii has a limited but 
effective set of virulence factors. One of them, AbOmpA, appears to simultaneously mediate 
host cell invasion, serum resistance and iron uptake, three potential prerequisites to 
virulence. This protein could therefore be a prime candidate for therapies targeting 
virulence mechanisms. Phospholipase D and recA are other candidates with an even wider 
spectrum that could benefit treatments of other infections. Other strategies targeting iron 
acquisition by the microbe could also prove successful. On the host side, boosting the 
activity of innate immunity such as neutrophils, or at least maintaining their proper 
numbers and function, could help slow or halt the progress of the pathogen.  
Given the wide variation in the clinical success, biofilm formation, disease pathogenesis and 
antibiotic resistance profiles of A. baumannii isolates, it is currently difficult to pinpoint 
which steps and factors are really essential for virulence and which merely modulate it. 
More research needs to be conducted to better understand pathogenesis, preferably in 
experimentally controlled conditions involving characterised hosts and bacteria. Given 
enough information, the ultimate goal would be to predict the course and outcome of the 
disease when encountering an unknown isolate, in order to take appropriate measures. 
Another benefit would be to identify new therapeutic targets to supplement and perhaps 
replace the shrinking arsenal of chemotherapeutic agents at our disposal. 
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